Mineralys Therapeutics (MLYS) Cash from Financing Activities (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Cash from Financing Activities data on file, last reported at $24.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 87.18% year-over-year to $24.3 million; the trailing twelve-month figure through Mar 2026 stood at $426.0 million (up 125.14% YoY), and the FY2025 full-year result was $591.0 million, up 408.86% from the prior year.
• Cash from Financing Activities slipped to $24.3 million in Q1 2026, from $96.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $295.2 million in Q3 2025 to a low of -$1.1 million in Q4 2022.
• A 5-year average of $62.5 million and a median of $9.8 million in 2025 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities plunged 100.54% in 2024 and surged 29518900.0% in 2025, its largest moves.
• Tracing MLYS's Cash from Financing Activities over 5 years: stood at -$1.1 million in 2022, then surged by 106.93% to $74000.0 in 2023, then grew by 21.62% to $90000.0 in 2024, then jumped by 107345.56% to $96.7 million in 2025, then slumped by 74.9% to $24.3 million in 2026.
• Business Quant data shows MLYS's Cash from Financing Activities at $24.3 million in Q1 2026, $96.7 million in Q4 2025, and $295.2 million in Q3 2025.